Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts
Zheng Chang, Patrick D. Quinn, Lauren M. O’Reilly, et al.
Biological Psychiatry (2019) Vol. 88, Iss. 6, pp. 452-458
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Luise Kazda, Katy Bell, Rae Thomas, et al.
JAMA Network Open (2021) Vol. 4, Iss. 4, pp. e215335-e215335
Open Access | Times Cited: 135
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study
Kenneth K. C. Man, Alexander Häge, Tobias Banaschewski, et al.
The Lancet Psychiatry (2023) Vol. 10, Iss. 5, pp. 323-333
Open Access | Times Cited: 49
Alcohol use disorders and ADHD
Mathias Luderer, Josep Antoni Ramos‐Quiroga, Stephen V. Faraone, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 128, pp. 648-660
Closed Access | Times Cited: 63
Identification of shared and differentiating genetic architecture for autism spectrum disorder, attention-deficit hyperactivity disorder and case subgroups
Manuel Mattheisen, Jakob Grove, Thomas D. Als, et al.
Nature Genetics (2022) Vol. 54, Iss. 10, pp. 1470-1478
Open Access | Times Cited: 52
Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes
Heidi Taipale, Jakob Bergström, Katalin Gémes, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e242859-e242859
Open Access | Times Cited: 9
Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review
Rafał Jaeschke, Ewelina Sujkowska, Magdalena Sowa-Kućma
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2667-2691
Open Access | Times Cited: 46
Mainstreaming adult ADHD into primary care in the UK: guidance, practice, and best practice recommendations
Philip Asherson, Laurence Leaver, Marios Adamou, et al.
BMC Psychiatry (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 38
Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment
Alisa R. Kosheleff, Oren Mason, Rakesh K. Jain, et al.
Journal of Attention Disorders (2023) Vol. 27, Iss. 7, pp. 669-697
Open Access | Times Cited: 22
Racial-Ethnic Differences in ADHD Diagnosis and Treatment During Adolescence and Early Adulthood
Sydney Adams, Tennisha N. Riley, Patrick D. Quinn, et al.
Psychiatric Services (2024) Vol. 75, Iss. 6, pp. 521-527
Closed Access | Times Cited: 6
Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder
Johannes Lieslehto, Jari Tiihonen, Markku Lähteenvuo, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2317130-e2317130
Open Access | Times Cited: 15
Stimulant medication and suicide mortality in attention-deficit hyperactivity disorder
Korie Rice, Talya Peltzman, Daniel J. Gottlieb, et al.
BJPsych Open (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Neurodevelopmental Disorders and Suicide: A Narrative Review
Antonella Gagliano, Carola Costanza, Irene Di Modica, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1627-1627
Open Access | Times Cited: 5
Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database
Jinhua Liu, Liping Xue, Fanxiang Zeng, et al.
European Child & Adolescent Psychiatry (2025)
Closed Access
Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
Wei Wei, Li Chen, Hui Zhou, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Risk factors for pre-adolescent onset suicidal behavior in a high-risk sample of youth
Jamie Zelazny, Bárbara Stanley, Giovanna Porta, et al.
Journal of Affective Disorders (2021) Vol. 290, pp. 292-299
Open Access | Times Cited: 17
An updated safety review of the current drugs for managing ADHD in children
Erika Ryst, Ann Childress
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 11, pp. 1025-1040
Closed Access | Times Cited: 4
Substance use and risk of suicide among adults who sought mental health and addiction specialty services through a centralised intake process in Nova Scotia: a cross-sectional study
Matiwos Soboka, Sherry H. Stewart, Philip G. Tibbo, et al.
BMJ Open (2024) Vol. 14, Iss. 10, pp. e086487-e086487
Open Access | Times Cited: 1
Retrospective analysis of adverse events associated with non-stimulant ADHD medications reported to the united states food and drug administration
Lindsy Pang, Romil Sareen
Psychiatry Research (2021) Vol. 300, pp. 113861-113861
Closed Access | Times Cited: 10
Associations of opioid prescription dose and discontinuation with risk of substance-related morbidity in long-term opioid therapy
Patrick D. Quinn, Zheng Chang, Matthew J. Bair, et al.
Pain (2021) Vol. 163, Iss. 4, pp. e588-e595
Open Access | Times Cited: 9
Cingulate white matter volume and associated cognitive and behavioral impulsivity in Veterans with a history of suicide behavior
Rebekah S. Huber, Erin McGlade, Margaret Legarreta, et al.
Journal of Affective Disorders (2020) Vol. 281, pp. 117-124
Closed Access | Times Cited: 9
Investigating the causal risk factors for self-harm by integrating Mendelian randomisation within twin modelling
Kai Xiang Lim, Olakunle Oginni, Kaili Rimfeld, et al.
Behavior Genetics (2022) Vol. 52, Iss. 6, pp. 324-337
Open Access | Times Cited: 6
Are attention-deficit/hyperactivity disorder symptoms associated with negative health outcomes in individuals with psychotic experiences? Findings from a cross-sectional study in Japan
Andrew Stickley, Aya Shirama, Tomiki Sumiyoshi
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 3
Attention‐deficit/hyperactivity disorder medication and risk of suicide attempt: A meta‐analysis of observational studies
Wenjuan Liu, Hongjing Mao, Lin-Lin Hu, et al.
Pharmacoepidemiology and Drug Safety (2020) Vol. 29, Iss. 11, pp. 1364-1372
Closed Access | Times Cited: 8
The role of sociodemographic and clinical factors in the initiation and discontinuation of attention deficit hyperactivity disorder medication among young adults in Sweden
Katalin Gémes, Heidi Taipale, Emma Björkenstam, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 2
Variation in ADHD Treatment by Mental Health Care Setting Among US College Students from 2019 to 2022
James Aluri, D. Wayne Goodman, Kevin M. Antshel, et al.
Journal of Attention Disorders (2023) Vol. 27, Iss. 12, pp. 1411-1419
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top